Interobserver Reproducibility of Percent Gleason Pattern 4 in Prostatic Adenocarcinoma on Prostate Biopsies

Evita T. Sadimin, Francesca Khani, Mairo Diolombi, Abdelrazak Meliti, Jonathan Ira Epstein

Research output: Contribution to journalArticle

Abstract

In the WHO Classification of Tumours of the Urinary System and Male Genital Organs published in 2016, it was officially recommended that the percent of Gleason pattern 4 (GP4) be reported on pathology reports to better reflect the extent in Gleason score 7 tumors. In this study we assessed the reproducibility of reporting GP4 on prostate biopsies. We analyzed prospectively 422 cores containing GP4 from our consult cases over a period of 2.5 months. The percent pattern 4 was assigned to all the cases in 10% increments from 0% to 100% (with the addition of 5%) by 1 of 4 fellows in urological pathology and by the expert urological pathologist. Out of 422 cores, 32% were an exact match and 75% were within ±10% (weighted κ [κW] value 0.67). Cases were further stratified on the basis of (1) scattered versus clustered GP4 in the background of Gleason pattern 3, (2) continuous versus discontinuous tumor involvement, (3) cribriform/glomeruloid pattern only versus poorly formed/fused pattern versus mixed cribriform and poorly formed/fused pattern, and (4) total tumor involvement of the core (≤10% vs. >10% of the core). No significant differences were observed in the first 3 variables. However, in cases with ≤10% involvement of the core, 61% were within ±10% (κW=0.50) compared with cases with >10% involvement of the core, in which 78% were within ±10% (κW=0.70). In summary, we showed that assessment of percent GP4 was relatively reproducible, with substantial agreement within ±10% in cases. However, with

Original languageEnglish (US)
JournalAmerican Journal of Surgical Pathology
DOIs
StateAccepted/In press - Aug 2 2016

Fingerprint

Prostate
Adenocarcinoma
Biopsy
Neoplasms
Male Genitalia
Pathology
Neoplasm Grading

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

Interobserver Reproducibility of Percent Gleason Pattern 4 in Prostatic Adenocarcinoma on Prostate Biopsies. / Sadimin, Evita T.; Khani, Francesca; Diolombi, Mairo; Meliti, Abdelrazak; Epstein, Jonathan Ira.

In: American Journal of Surgical Pathology, 02.08.2016.

Research output: Contribution to journalArticle

@article{1ba21dbb85ad4bfd9cf4b74dfa058ccf,
title = "Interobserver Reproducibility of Percent Gleason Pattern 4 in Prostatic Adenocarcinoma on Prostate Biopsies",
abstract = "In the WHO Classification of Tumours of the Urinary System and Male Genital Organs published in 2016, it was officially recommended that the percent of Gleason pattern 4 (GP4) be reported on pathology reports to better reflect the extent in Gleason score 7 tumors. In this study we assessed the reproducibility of reporting GP4 on prostate biopsies. We analyzed prospectively 422 cores containing GP4 from our consult cases over a period of 2.5 months. The percent pattern 4 was assigned to all the cases in 10{\%} increments from 0{\%} to 100{\%} (with the addition of 5{\%}) by 1 of 4 fellows in urological pathology and by the expert urological pathologist. Out of 422 cores, 32{\%} were an exact match and 75{\%} were within ±10{\%} (weighted κ [κW] value 0.67). Cases were further stratified on the basis of (1) scattered versus clustered GP4 in the background of Gleason pattern 3, (2) continuous versus discontinuous tumor involvement, (3) cribriform/glomeruloid pattern only versus poorly formed/fused pattern versus mixed cribriform and poorly formed/fused pattern, and (4) total tumor involvement of the core (≤10{\%} vs. >10{\%} of the core). No significant differences were observed in the first 3 variables. However, in cases with ≤10{\%} involvement of the core, 61{\%} were within ±10{\%} (κW=0.50) compared with cases with >10{\%} involvement of the core, in which 78{\%} were within ±10{\%} (κW=0.70). In summary, we showed that assessment of percent GP4 was relatively reproducible, with substantial agreement within ±10{\%} in cases. However, with",
author = "Sadimin, {Evita T.} and Francesca Khani and Mairo Diolombi and Abdelrazak Meliti and Epstein, {Jonathan Ira}",
year = "2016",
month = "8",
day = "2",
doi = "10.1097/PAS.0000000000000714",
language = "English (US)",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Interobserver Reproducibility of Percent Gleason Pattern 4 in Prostatic Adenocarcinoma on Prostate Biopsies

AU - Sadimin, Evita T.

AU - Khani, Francesca

AU - Diolombi, Mairo

AU - Meliti, Abdelrazak

AU - Epstein, Jonathan Ira

PY - 2016/8/2

Y1 - 2016/8/2

N2 - In the WHO Classification of Tumours of the Urinary System and Male Genital Organs published in 2016, it was officially recommended that the percent of Gleason pattern 4 (GP4) be reported on pathology reports to better reflect the extent in Gleason score 7 tumors. In this study we assessed the reproducibility of reporting GP4 on prostate biopsies. We analyzed prospectively 422 cores containing GP4 from our consult cases over a period of 2.5 months. The percent pattern 4 was assigned to all the cases in 10% increments from 0% to 100% (with the addition of 5%) by 1 of 4 fellows in urological pathology and by the expert urological pathologist. Out of 422 cores, 32% were an exact match and 75% were within ±10% (weighted κ [κW] value 0.67). Cases were further stratified on the basis of (1) scattered versus clustered GP4 in the background of Gleason pattern 3, (2) continuous versus discontinuous tumor involvement, (3) cribriform/glomeruloid pattern only versus poorly formed/fused pattern versus mixed cribriform and poorly formed/fused pattern, and (4) total tumor involvement of the core (≤10% vs. >10% of the core). No significant differences were observed in the first 3 variables. However, in cases with ≤10% involvement of the core, 61% were within ±10% (κW=0.50) compared with cases with >10% involvement of the core, in which 78% were within ±10% (κW=0.70). In summary, we showed that assessment of percent GP4 was relatively reproducible, with substantial agreement within ±10% in cases. However, with

AB - In the WHO Classification of Tumours of the Urinary System and Male Genital Organs published in 2016, it was officially recommended that the percent of Gleason pattern 4 (GP4) be reported on pathology reports to better reflect the extent in Gleason score 7 tumors. In this study we assessed the reproducibility of reporting GP4 on prostate biopsies. We analyzed prospectively 422 cores containing GP4 from our consult cases over a period of 2.5 months. The percent pattern 4 was assigned to all the cases in 10% increments from 0% to 100% (with the addition of 5%) by 1 of 4 fellows in urological pathology and by the expert urological pathologist. Out of 422 cores, 32% were an exact match and 75% were within ±10% (weighted κ [κW] value 0.67). Cases were further stratified on the basis of (1) scattered versus clustered GP4 in the background of Gleason pattern 3, (2) continuous versus discontinuous tumor involvement, (3) cribriform/glomeruloid pattern only versus poorly formed/fused pattern versus mixed cribriform and poorly formed/fused pattern, and (4) total tumor involvement of the core (≤10% vs. >10% of the core). No significant differences were observed in the first 3 variables. However, in cases with ≤10% involvement of the core, 61% were within ±10% (κW=0.50) compared with cases with >10% involvement of the core, in which 78% were within ±10% (κW=0.70). In summary, we showed that assessment of percent GP4 was relatively reproducible, with substantial agreement within ±10% in cases. However, with

UR - http://www.scopus.com/inward/record.url?scp=84980350473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980350473&partnerID=8YFLogxK

U2 - 10.1097/PAS.0000000000000714

DO - 10.1097/PAS.0000000000000714

M3 - Article

C2 - 27487740

AN - SCOPUS:84980350473

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

ER -